Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22067397 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Conditions: Leiomyosarcoma;   Liposarcoma;   Osteosarcoma;   Sarcoma, Soft Tissue;   Metastases
Intervention: Drug: ridaforolimus

Indicates status has not been verified in more than two years